MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Recursion Pharmaceuticals Inc

Închisă

SectorSănătate

5.26 1.15

Rezumat

Modificarea prețului

24h

Curent

Minim

5.17

Maxim

5.32

Indicatori cheie

By Trading Economics

Venit

-24M

-202M

Vânzări

10M

15M

EPS

-0.5

Marjă de profit

-1,373.259

Angajați

800

EBITDA

-26M

-191M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+18.6% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-260M

2.1B

Deschiderea anterioară

4.11

Închiderea anterioară

5.26

Sentimentul știrilor

By Acuity

60%

40%

306 / 375 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 iul. 2025, 23:55 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 iul. 2025, 22:35 UTC

Achiziții, Fuziuni, Preluări

South32 Expects to Complete Transaction in Late 2025

6 iul. 2025, 22:35 UTC

Achiziții, Fuziuni, Preluări

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 iul. 2025, 22:34 UTC

Achiziții, Fuziuni, Preluări

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 iul. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 iul. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 iul. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 iul. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 iul. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 iul. 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 iul. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 iul. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 iul. 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 iul. 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 iul. 2025, 15:49 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 iul. 2025, 15:49 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 iul. 2025, 15:49 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole Received All Required Authorizations

4 iul. 2025, 15:48 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 iul. 2025, 15:47 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: Agreement Was Announced on Dec. 19

4 iul. 2025, 15:47 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 iul. 2025, 15:46 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 iul. 2025, 14:30 UTC

Achiziții, Fuziuni, Preluări

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 iul. 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 iul. 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 iul. 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 iul. 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 iul. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 iul. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

18.6% sus

Prognoză pe 12 luni

Medie 6.25 USD  18.6%

Maxim 8 USD

Minim 4 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.15 / 4.75Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

306 / 375 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.